With the broader market facing volatility, a clutch of experts are recommending investors to look beyond mega-cap stocks like Meta, Amazon, and Netflix for opportunities in stocks with strong earnings growth potential.
According to Investor’s Business Daily, several under-the-radar companies are expected to post explosive earnings gains in the coming year, making them attractive picks for those seeking substantial portfolio growth.
Following are five such stocks that could supercharge your portfolios:
Privia Health (PRVA) set for triple-digit growth
Privia Health (PRVA), a provider of medical technology solutions, is set to see its earnings per share soar by 125% in the next year, with a further 42% increase expected the following year, according to FactSet.
The company reassured investors with its 2025 outlook despite challenges in the Medicare Advantage market.
Privia Health stock has surged about 28% in 2025, significantly outperforming the broader US market, which is down by approximately 1%.
Corcept Therapeutics (CORT) rides biotech wave
Corcept Therapeutics (CORT), a biotech firm focused on cortisol-modulating drugs, is another standout.
Analysts project earnings per share will rise 55% in 2025 and another 86% in 2026.
Sales are expected to jump by 34% and 30% over the next two years, respectively.
Despite missing Q4 estimates, Corcept provided an upbeat 2025 forecast on Feb. 26.
The stock has climbed nearly 20% year to date.
TG Therapeutics (TGTX) delivers a stunning turnaround
TG Therapeutics (TGTX) has emerged as a major player in the multiple sclerosis treatment market with its flagship drug Briumvi.
The company, which recently turned profitable, is forecast to see a staggering 570% surge in earnings per share in 2025, driven by a projected 70% increase in sales.
Following a strong Q4 earnings report, shares surged 17% on Monday. Year to date, TGTX stock has gained 16.5%.
TKO Group (TKO) flexes entertainment dominance
TKO Group (TKO), the owner of Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE), is poised for a dramatic earnings surge.
Analysts expect per-share earnings to jump to $3.04 in 2025 from just two cents in 2024, followed by another 73% increase in 2026. Sales are projected to grow 15.5% next year.
The company posted a strong Q4 report, swinging to a profit for 2024, and TKO stock is up 4% year to date.
Gilead Sciences (GILD) rebounds with strong forecast
Gilead Sciences (GILD), a leading biopharmaceutical company, is on track to reverse three consecutive years of earnings decline.
Fuelled by strong sales of its HIV treatment Biktarvy and its Covid therapy Veklury, Gilead is projected to see a 72% rise in earnings per share in 2025, with an additional 5.5% increase in 2026.
The stock has risen 25% year to date.
The post Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025 appeared first on Invezz
